President, Global Head of Research and Development · BeOne Medicines (BGNE)

Lai Wang

Lai Wang, President and Global Head of Research and Development at BeOne Medicines, received total compensation of 18319310 USD in fiscal year 2025. This amount included a base salary of 659492 USD, a cash bonus of 585629 USD, and stock-based compensation of 16999485 USD.

FY2025 is the first fiscal year CompBrief holds for Lai Wang as a named executive officer of BeOne Medicines; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$18,319,310

Compensation figures as of the proxy filed April 28, 2026 (DEF 14A).

Lai Wang compensation by year

BeOne Medicines Summary Compensation Table · the one fiscal year held
In US dollars, as BeOne Medicines reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$659,492
Bonus$0
Stock awards$15,249,603
Option awards$1,749,882
Non-equity incentive$585,629
Pension and deferred compensation$0
All other$74,704
Total$18,319,310

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BeOne Medicines DEF 14A filed April 28, 2026, accession 0001104659-26-049655, and prior-year filings. Open the filing on EDGAR.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU427,895$9,999,906—
RSU181,857$4,249,998—
RSU126,711$2,961,236—
PSU115,154$2,691,149—
RSU86,359$2,018,210—
RSU66,833$1,561,887—
PSU56,329$1,316,409—
RSU55,029$1,286,028—
RSU31,304$732,486—
Option190,424—$16.41
Option88,647—$11.98
Option198,913—$12.23

Per the Outstanding Equity Awards at Fiscal Year-End table in BeOne Medicines's FY2025 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 13 award rows shown.

BeOne Medicines’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Lai Wang · this pagePresident, Global Head of Research and Development$18,319,310
John OylerCo-Founder, Chairman and Chief Executive Officer$17,943,521
Xiaobin WuPresident and Chief Operating Officer$12,029,451
Aaron RosenbergChief Financial Officer$6,428,374
Chan LeeSenior Vice President, General Counsel and Corporate Secretary$5,055,306

The full BeOne Medicines compensation record

free company brief

This page is one person within BeOne Medicines's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order BeOne Medicines's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BeOne Medicines's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy